Skip to main content
Journal cover image

Cost-effectiveness analysis of annual screening strategies for endometrial cancer.

Publication ,  Journal Article
Havrilesky, LJ; Maxwell, GL; Myers, ER
Published in: Am J Obstet Gynecol
June 2009

OBJECTIVE: The objective of the study was to determine the cost-effectiveness of annual screening tests for endometrial cancer. STUDY DESIGN: Markov state transition model of the natural history of endometrial cancer used as the design for the study. Incidence was modeled for the general population and high risk groups (obese, body mass index [BMI] of >or= 30 kg/m(2); tamoxifen users). Strategies evaluated were no screening, annual endometrial biopsy, annual endovaginal ultrasound, and annual serum screening. Serum screening was based on a recently described biomarker panel (sensitivity of 0.98, specificity of 0.98). RESULTS: In the general population model, no screening was least expensive, whereas annual serum screening age at 50-75 years had incremental cost-effectiveness ratio (ICER) of $60,363 per year of life saved (YLS) compared with no screening. In a high-risk population (obesity, BMI of >or= 30 kg/m(2)), annual serum screening at age 45-80 years had ICER of $41,226 per YLS compared with no screening. Annual endometrial biopsy and annual transvaginal ultrasound were dominated. CONCLUSION: Annual serum screening for endometrial cancer has the potential to be cost effective when applied to high-risk populations.

Duke Scholars

Published In

Am J Obstet Gynecol

DOI

EISSN

1097-6868

Publication Date

June 2009

Volume

200

Issue

6

Start / End Page

640.e1 / 640.e8

Location

United States

Related Subject Headings

  • Obstetrics & Reproductive Medicine
  • Middle Aged
  • Mass Screening
  • Humans
  • Female
  • Endometrial Neoplasms
  • Cost-Benefit Analysis
  • Aged, 80 and over
  • Aged
  • 3215 Reproductive medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Havrilesky, L. J., Maxwell, G. L., & Myers, E. R. (2009). Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol, 200(6), 640.e1-640.e8. https://doi.org/10.1016/j.ajog.2009.02.022
Havrilesky, Laura J., G Larry Maxwell, and Evan R. Myers. “Cost-effectiveness analysis of annual screening strategies for endometrial cancer.Am J Obstet Gynecol 200, no. 6 (June 2009): 640.e1-640.e8. https://doi.org/10.1016/j.ajog.2009.02.022.
Havrilesky LJ, Maxwell GL, Myers ER. Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol. 2009 Jun;200(6):640.e1-640.e8.
Havrilesky, Laura J., et al. “Cost-effectiveness analysis of annual screening strategies for endometrial cancer.Am J Obstet Gynecol, vol. 200, no. 6, June 2009, pp. 640.e1-640.e8. Pubmed, doi:10.1016/j.ajog.2009.02.022.
Havrilesky LJ, Maxwell GL, Myers ER. Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol. 2009 Jun;200(6):640.e1-640.e8.
Journal cover image

Published In

Am J Obstet Gynecol

DOI

EISSN

1097-6868

Publication Date

June 2009

Volume

200

Issue

6

Start / End Page

640.e1 / 640.e8

Location

United States

Related Subject Headings

  • Obstetrics & Reproductive Medicine
  • Middle Aged
  • Mass Screening
  • Humans
  • Female
  • Endometrial Neoplasms
  • Cost-Benefit Analysis
  • Aged, 80 and over
  • Aged
  • 3215 Reproductive medicine